Cardiff Oncology, Inc. 8-K

What Happened

• Cardiff Oncology, Inc. announced it filed a lawsuit on May 19, 2026 in the U.S. District Court for the Southern District of California against Nerviano Medical Sciences S.r.L. (NMS).
• The complaint seeks injunctive relief forcing NMS to continue performing under the parties’ license agreement for the cancer drug candidate onvansertib and a declaratory judgment that Cardiff did not materially breach the agreement.
• NMS had sent a written notice (previously disclosed on February 24, 2026) alleging Cardiff breached the agreement by not naming an NMS employee as a joint inventor on Cardiff’s U.S. Patent Nos. 12,144,813 and 12,263,173 and by not agreeing to file a joint invention continuation. Cardiff disputes those claims and says the agreement does not require naming NMS employees on inventions made exclusively by Cardiff or making inaccurate inventorship statements to the U.S. Patent and Trademark Office.

Key Details

• Filing date: May 19, 2026; court: U.S. District Court, Southern District of California.
• Disputed patents: U.S. Patent Nos. 12,144,813 and 12,263,173.
• Prior notice from NMS alleging breach was disclosed Feb 24, 2026.
• Requested relief: injunctive relief to compel NMS performance and a declaratory judgment that Cardiff did not breach.

Why It Matters

• The dispute centers on inventorship and control under the onvansertib license, which affects intellectual property rights tied to Cardiff’s drug candidate.
• Litigation could affect the company’s ability to commercialize or enforce patents, distract management, and create legal costs; the filing signals Cardiff seeks judicial confirmation that it remains in compliance.
• The 8-K contains no financial estimates or settlement terms; outcomes and potential impacts on timelines or value depend on future legal developments.